ADHD Medication in Australia: A Complete Guide (2026)

Australia has five main ADHD medications in several formulations, all available through the PBS with appropriate authorisation:

Stimulant medications (Schedule 8 — first-line treatment):

Non-stimulant medications (second-line):

The AADPA guideline recommends stimulants as first-line treatment. Non-stimulants are recommended when stimulants are contraindicated, cause intolerable side effects, or are ineffective. Third-line options (bupropion, clonidine, modafinil) are used off-label.

From 1 January 2026, PBS co-payments are:

• Annual medication cost estimates:**
• General patient: $300-$650/year (12-26 scripts at $25 each, before Safety Net)
• Concession holder: $92-$200/year (12-26 scripts at $7.70 each, before Safety Net)
• Without PBS subsidy: $1,200+/year

PBS authority is required for stimulant medications. Your prescriber obtains this electronically when writing the script — it's an administrative step, not an extra cost to you.

Important for adults with late diagnosis: Retrospective diagnosis (confirming symptoms were present before age 12, even if only diagnosed now) qualifies for PBS subsidies for Vyvanse and Ritalin LA. This was expanded in February 2021 and was a landmark policy change. You don't need to have been diagnosed as a child — you need a clinician to confirm childhood symptom onset.

Vyvanse price note: A significant PBS price change brought Vyvanse to $55 per unit across all strengths from December 2025.

Prescribing rules vary significantly by state and are changing rapidly:

A national advisory group is working on harmonised drugs and poisons legislation, expected to report with a 12-month plan by early 2026.

Interstate telehealth note: Schedule 8 prescribing via telehealth requires compliance with the regulations of both the prescriber's state and the state where the patient is physically located at the time of consultation. Some states (e.g. Tasmania) do not allow interstate practitioners to be authorised for Schedule 8 prescribing at all. Check your state's specific rules.

When starting ADHD medication, the standard approach is "start low, go slow":

• Initial prescription — your prescriber starts at the lowest available dose
• Gradual increase — small dose increments at weekly, fortnightly, or monthly intervals
• Finding the right dose — typically takes 4-8 weeks, sometimes up to 12 weeks
• Optimal dose — the dose where symptoms improve meaningfully without intolerable side effects

• What to expect during titration:**
• Some people notice improvement from the first dose; others need several adjustments
• Your prescriber will ask you to track symptoms and side effects between appointments
• Heart rate and blood pressure are checked at each dose change
• Expect appointments every 1-3 weeks during titration

Important: Dosing is individualised based on response, NOT severity of ADHD, age, or body weight. A small person may need a higher dose than a large person, and vice versa.

If one medication doesn't work: A partial response to one stimulant class (methylphenidate-based) may warrant switching to the other class (amphetamine-based), or vice versa. When two stimulant classes are tried sequentially, response rates reach 80-90%.

• Common side effects (most are mild and settle within 2-4 weeks):**
• Decreased appetite (most common — affects ~80% of patients on stimulants)
• Difficulty sleeping (particularly with dexamfetamine; timing doses earlier can help)
• Headache
• Dry mouth
• Increased heart rate (small rise, typically clinically insignificant)
• Mild blood pressure increase
• Stomach discomfort or nausea
• Anxiety or irritability (usually dose-related)

• Stimulant comparison:**
• Dexamfetamine tends to cause more insomnia than methylphenidate
• Dexamfetamine may cause more irritability or mood changes in some people
• Both cause appetite suppression to a similar degree

• Serious side effects (rare):**
• Cardiovascular events: FDA-commissioned studies (2011) found no association between serious cardiovascular events and medical use of stimulants at therapeutic doses
• Psychosis or mania: very rare at therapeutic doses
• Growth suppression: possible in children; monitored during treatment

• Monitoring requirements (per AADPA guideline):**
• Baseline heart rate and blood pressure (with age-appropriate cuff)
• ECG is NOT routinely required unless there's a personal or family history of arrhythmias, cardiac malformations, or sudden unexpected death
• Heart rate and BP monitored before and after each dose change, then every 6 months
• Height and weight monitoring in children at each review
• Routine blood tests are NOT required unless clinically indicated

Methylphenidate shortages have been ongoing since 2023 and are expected to continue through 2026. Key details:

• Concerta (modified-release methylphenidate): shortage notification extended until end of 2026
• From January 2024 to May 2025, prescriptions filled increased by 88% for methylphenidate, straining supply
• This is part of a global ADHD medication shortage driven by surging diagnosis rates worldwide

• What the TGA has done:**
• Convened a Methylphenidate Medicine Shortage Action Group
• Approved supply of overseas-registered methylphenidate products under Section 19A of the Therapeutic Goods Act (emergency importation)
• Published clinical guidance for managing shortages

• What to do if your medication is unavailable:**
• Ask your pharmacist to check other pharmacies or order stock
• Contact your prescriber about alternative formulations (e.g., switching from Concerta to Ritalin LA, or from modified-release to immediate-release)
• AADPA has published dose conversion tables for switching between formulations
• Don't stop medication abruptly — work with your prescriber to manage any transition

Roadside drug testing: Australian roadside oral fluid tests screen for methamphetamine, MDMA, and THC (NSW and QLD also test for cocaine). They will NOT detect prescription ADHD medications (dexamfetamine, methylphenidate, lisdexamfetamine). If a false positive occurs (extremely rare), laboratory confirmation testing does not test for prescribed ADHD medications.

• Practical advice:**
• Keep a letter from your prescriber confirming you are prescribed ADHD medication
• For most people with ADHD, stimulant medication improves driving ability (better attention, fewer impulsive decisions)
• Research shows ADHD medication reduces crash risk by 38-42%

Legal framework: It is illegal to drive while impaired by any drug, including prescriptions. However, having a valid prescription and following prescriber advice provides a statutory defence against impairment-based charges in most states. The Austroads Fitness to Drive standards (2022) do not impose blanket restrictions based on ADHD diagnosis — assessment is individualised.

If you're pregnant, planning pregnancy, or breastfeeding, discuss ADHD medication with your prescriber:

• Pregnancy:**
• Methylphenidate was reclassified to Category D by the TGA (evidence of increased foetal cardiac malformations from large observational studies)
• Amphetamines (dexamfetamine, lisdexamfetamine) are generally Category B3; most studies suggest no increased birth defect risk, but may slightly increase risk of premature birth and low birth weight
• The decision to continue or stop medication during pregnancy requires weighing the risks of medication against the risks of untreated ADHD

• Breastfeeding:**
• Methylphenidate levels in breast milk are very low and not detectable in infant serum — breastfeeding is generally compatible
• Amphetamines: benefits of breastfeeding generally outweigh risks of concurrent stimulant treatment
• Methylphenidate has a slight preference over amphetamines during breastfeeding, but both are considered compatible

This is a shared decision between you and your prescriber. There is no one-size-fits-all answer — it depends on your symptom severity, functional impact, and individual risk factors.